Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHGCY Chugai Pharmaceutical	$24.56 +2.0%	$25.02	$19.51 ▼ $31.26	$79.25B	0.65	336,910 shs	69,048 shs
DSNKY Daiichi Sankyo	$24.63 -0.4%	$24.09	$20.92 ▼ $42.48	$46.83B	N/A	222,117 shs	195,871 shs
SDZNY Sandoz Group	$56.99 0.0%	$54.42	$35.61 ▼ $60.69	$25.08B	0.6	20,637 shs	20,766 shs
ZTS Zoetis	$147.40 +1.1%	$158.51	$139.70 ▼ $200.33	$64.91B	0.88	3.15 million shs	3.15 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHGCY Chugai Pharmaceutical	+1.99%	-0.61%	-0.49%	-17.61%	+12.66%
DSNKY Daiichi Sankyo	+0.12%	+0.53%	+8.03%	-4.94%	-39.85%
SDZNY Sandoz Group	-0.04%	-4.09%	+5.65%	+28.30%	+31.24%
ZTS Zoetis	+1.13%	-2.98%	-7.35%	-6.37%	-18.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CHGCY Chugai Pharmaceutical	2.0179 of 5 stars	0.0	5.0	2.5	0.0	2.8	0.0	0.6
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SDZNY Sandoz Group	1.6372 of 5 stars	0.0	3.0	0.8	0.0	1.7	0.0	2.5
ZTS Zoetis	4.9403 of 5 stars	4.4	3.0	4.2	0.4	3.6	2.5	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHGCY Chugai Pharmaceutical	0.00	N/A	N/A	N/A
DSNKY Daiichi Sankyo	4.00	Strong Buy	N/A	N/A
SDZNY Sandoz Group	2.00	Hold	N/A	N/A
ZTS Zoetis	2.70	Moderate Buy	$204.63	38.82% Upside

Current Analyst Ratings Breakdown

Latest SDZNY, CHGCY, ZTS, and DSNKY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	ZTS Zoetis	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	ZTS Zoetis	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$180.00 ➝ $155.00
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00
6/6/2025	DSNKY Daiichi Sankyo	Nomura Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$205.00 ➝ $210.00
5/7/2025	ZTS Zoetis	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$189.00 ➝ $170.00
5/2/2025	SDZNY Sandoz Group	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Moderate Buy

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHGCY Chugai Pharmaceutical	$7.74B	10.44	$0.86 per share	28.60	$3.81 per share	6.45
DSNKY Daiichi Sankyo	$12.39B	3.77	$1.25 per share	19.69	$5.61 per share	4.39
SDZNY Sandoz Group	$10.36B	2.42	$2.67 per share	21.33	$18.56 per share	3.07
ZTS Zoetis	$9.26B	7.09	$7.15 per share	20.62	$10.57 per share	13.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHGCY Chugai Pharmaceutical	$2.56B	$0.79	31.09	31.49	N/A	33.08%	21.35%	18.66%	N/A
DSNKY Daiichi Sankyo	$1.95B	$1.03	23.91	22.60	1.26	15.65%	17.92%	8.61%	N/A
SDZNY Sandoz Group	$1M	N/A	0.00	17.17	0.99	N/A	N/A	N/A	8/7/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.57	26.46	21.84	2.42	27.12%	55.48%	19.14%	8/5/2025 (Estimated)

Latest SDZNY, CHGCY, ZTS, and DSNKY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	ZTS Zoetis	$1.61	N/A	N/A	N/A	$2.41 billion	N/A
7/24/2025	Q2 2025	CHGCY Chugai Pharmaceutical	N/A	$0.20	N/A	$0.20	N/A	$2.01 billion
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHGCY Chugai Pharmaceutical	$0.26	1.06%	N/A	32.91%	N/A
DSNKY Daiichi Sankyo	$0.29	1.18%	N/A	28.16%	N/A
SDZNY Sandoz Group	$0.44	0.77%	N/A	N/A	N/A
ZTS Zoetis	$2.00	1.36%	N/A	35.91%	14 Years

Latest SDZNY, CHGCY, ZTS, and DSNKY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHGCY Chugai Pharmaceutical	N/A	7.28	6.16
DSNKY Daiichi Sankyo	0.06	2.53	1.85
SDZNY Sandoz Group	0.57	1.24	0.79
ZTS Zoetis	1.12	1.74	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CHGCY Chugai Pharmaceutical	0.01%
DSNKY Daiichi Sankyo	N/A
SDZNY Sandoz Group	0.06%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
CHGCY Chugai Pharmaceutical	N/A
DSNKY Daiichi Sankyo	N/A
SDZNY Sandoz Group	N/A
ZTS Zoetis	0.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CHGCY Chugai Pharmaceutical	7,778	3.29 billion	N/A	Not Optionable
DSNKY Daiichi Sankyo	17,435	1.89 billion	N/A	Not Optionable
SDZNY Sandoz Group	23,406	440.00 million	N/A	Not Optionable
ZTS Zoetis	13,800	445.21 million	444.41 million	Optionable

SDZNY, CHGCY, ZTS, and DSNKY Headlines

Recent News About These Companies

Zoetis (ZTS) Stock Rated Overweight as Key Franchises Remain Strong Amid Competition

4 hours ago | msn.com

UNIVEST FINANCIAL Corp Sells 12,406 Shares of Zoetis Inc. (NYSE:ZTS)

August 2 at 6:33 AM | marketbeat.com

Heritage Wealth Advisors Has $746,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

August 2 at 6:21 AM | marketbeat.com

Arkadios Wealth Advisors Has $1.82 Million Holdings in Zoetis Inc. (NYSE:ZTS)

August 2 at 5:29 AM | marketbeat.com

Market Whales and Their Recent Bets on ZTS Options

August 2 at 3:24 AM | benzinga.com

Zoetis Inc. (NYSE:ZTS) Receives Average Recommendation of "Moderate Buy" from Analysts

August 2 at 2:51 AM | americanbankingnews.com

Zoetis Inc. (NYSE:ZTS) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 2 at 2:49 AM | marketbeat.com

Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect

August 1 at 12:26 PM | zacks.com

Zacks Research Has Bullish Forecast for Zoetis Q1 Earnings

August 1 at 7:25 AM | marketbeat.com

Davis R M Inc. Has $20.92 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

August 1 at 6:15 AM | marketbeat.com

Bayforest Capital Ltd Buys 1,843 Shares of Zoetis Inc. (NYSE:ZTS)

August 1 at 5:53 AM | marketbeat.com

Harvest Fund Management Co. Ltd Takes $660,000 Position in Zoetis Inc. (NYSE:ZTS)

August 1 at 5:40 AM | marketbeat.com

Countdown to Zoetis (ZTS) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

July 31 at 10:16 AM | zacks.com

LPL Financial LLC Boosts Position in Zoetis Inc. (NYSE:ZTS)

July 31 at 5:02 AM | marketbeat.com

Here's Why Zoetis (ZTS) Fell More Than Broader Market

July 30 at 7:16 PM | zacks.com

Natixis Advisors LLC Has $154.10 Million Holdings in Zoetis Inc. (NYSE:ZTS)

July 30 at 5:38 AM | marketbeat.com

SSA Swiss Advisors AG Invests $3.02 Million in Zoetis Inc. (NYSE:ZTS)

July 30 at 5:38 AM | marketbeat.com

Bristol Gate Capital Partners Inc. Buys 7,804 Shares of Zoetis Inc. (NYSE:ZTS)

July 30 at 4:11 AM | marketbeat.com

SlateStone Wealth LLC Acquires 1,934 Shares of Zoetis Inc. (NYSE:ZTS)

July 30 at 4:11 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Bought by Mesirow Financial Investment Management Inc.

July 30 at 4:11 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Dearborn Partners LLC

July 30 at 4:11 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDZNY, CHGCY, ZTS, and DSNKY Company Descriptions

Chugai Pharmaceutical OTCMKTS:CHGCY

$24.56 +0.48 (+1.99%)

As of 08/1/2025 03:59 PM Eastern

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Daiichi Sankyo OTCMKTS:DSNKY

$24.63 -0.09 (-0.36%)

As of 08/1/2025 03:59 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Sandoz Group OTCMKTS:SDZNY

$56.99 -0.02 (-0.04%)

As of 08/1/2025 03:51 PM Eastern

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

Zoetis NYSE:ZTS

$147.40 +1.61 (+1.10%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$147.36 -0.03 (-0.02%)

As of 08/1/2025 06:14 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time